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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.041Objective: Ischemic heart failure is an increasingly prevalent global health concern
with major morbidity and mortality. Currently, therapies are limited, and novel
revascularization methods might have a role. This study examined enhancing
endogenous myocardial revascularization by expanding bone marrow–derived en-
dothelial progenitor cells with the marrow stimulant granulocyte-monocyte colony-
stimulating factor and recruiting the endothelial progenitor cells with intramyocar-
dial administration of the potent endothelial progenitor cell chemokine stromal
cell–derived factor.
Methods: Ischemic cardiomyopathy was induced in Lewis rats (n 40) through left
anterior descending coronary artery ligation. After 3 weeks, animals were random-
ized into 4 groups: saline control, granulocyte-monocyte colony-stimulating factor
only (GM-CSF only), stromal cell–derived factor only (SDF only), and combined
stromal cell–derived factor/granulocyte-monocyte colony-stimulating factor (SDF/
GM-CSF) (n  10 each). After another 3 weeks, hearts were analyzed for endo-
thelial progenitor cell density by endothelial progenitor cell marker colocalization
immunohistochemistry, vasculogenesis by von Willebrand immunohistochemistry,
ventricular geometry by hematoxylin-and-eosin microscopy, and in vivo myocardial
function with an intracavitary pressure–volume conductance microcatheter.
Results: The saline control, GM-CSF only, and SDF only groups were equivalent.
Compared with the saline control group, animals in the SDF/GM-CSF group
exhibited increased endothelial progenitor cell density (21.7  3.2 vs 9.6  3.1
CD34/vascular endothelial growth factor receptor 2–positive cells per high-power
field, P  .01). There was enhanced vascularity (44.1  5.5 versus 23.8  2.2 von
Willebrand factor–positive vessels per high-power field, P  .007). SDF/GM-CSF
group animals experienced less adverse ventricular remodeling, as manifested by
less cavitary dilatation (9.8  0.1 mm vs 10.1  0.1 mm [control], P  .04) and
increased border-zone wall thickness (1.78  0.19 vs 1.41  0.16 mm [control],
P  .03). (SDF/GM-CSF group animals had improved cardiac function compared
with animals in the saline control group (maximum pressure: 93.9  3.2 vs 71.7 
3.1 mm Hg, P  .001; maximum dP/dt: 3513  303 vs 2602  201 mm Hg/s,
P  .05; cardiac output: 21.3  2.7 vs 13.3  1.3 mL/min, P  .01; end-systolic
pressure-volume relationship slope: 1.7  0.4 vs 0.5  0.2 mm Hg/L, P  .01.)
Conclusion: This novel revascularization strategy of bone marrow stimulation and
intramyocardial delivery of the endothelial progenitor cell chemokine stromal
cell–derived factor yielded significantly enhanced myocardial endothelial progeni-
tor cell density, vasculogenesis, geometric preservation, and contractility in a model
of ischemic cardiomyopathy.
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CSPCongestive heart failure (CHF), predominantly a con-sequence of ischemic heart disease, is an increas-ingly prevalent global health concern. In the United
States there are 5 million patients with CHF and an esti-
mated additional 5 million persons with asymptomatic left
ventricular dysfunction.1 CHF accounts for 1 million hos-
pital admissions and 15 million office visits annually. Cur-
rent medical therapy for ischemic cardiomyopathy is limited
to adjustment of preload and afterload and, in limited cir-
cumstances, contractility. Surgical therapies include valvu-
lar reconstruction, ventricular assist devices, and transplan-
tation for limited patients. Myocardial revascularization as a
therapy for ischemic ventricular dysfunction has produced
encouraging improvement in global ventricular function.2
These clinical findings have prompted extensive investiga-
tion into alternative revascularization strategies because the
vast majority of patients with ischemic cardiomyopathy do
not have anatomically correctable coronary artery disease.
Recent studies have focused on the use of angiogenic fac-
tors, such as fibroblast growth factor,3 vascular endothelial
growth factor (VEGF),4 and hepatocyte growth factor.5 The
latest investigations have focused on the transplantation of
ex vivo expanded endothelial progenitor cells (EPCs) as an
alternate means of revascularizing ischemic cardiomyo-
pathic hearts.6
An EPC is a hematopoietic bone marrow–derived cell
that expresses CD34 and VEGF receptor 2 (VEGFR2) and
differentiates into an endothelial cell.7 EPCs modulate the
re-endothelialization of injured blood vessels8 and the de
novo endothelialization of intravascular implants, such as
valvular prostheses, vascular grafts, and ventricular assist
devices.9 EPCs also participate in neovascularization in
regions of ischemia.10 Transplantation of EPCs as a practi-
cal therapeutic modality is limited by requisite large vol-
umes of source blood or marrow, extensive cell sorting and
purification techniques, and lengthy propagation periods.
As an alternative to EPC transplantation, we investigated
a strategy of enhancing native EPC recruitment to treat
ischemic cardiomyopathy by combining marrow prolifera-
tion and localized chemotactic stimuli. Granulocyte-mono-
cyte colony-stimulating factor (GM-CSF), a global bone
marrow stimulant, increases total marrow and circulating
levels of EPCs.11 It is reported that EPC levels begin to
increase immediately after GM-CSF administration, con-
tinue to increase during repeated administration, and then
peak and remain increased for at least 1 week after ceasing
administration.11 Stromal cell–derived factor 1 (SDF) is
an EPC chemokine that promotes the transendothelial mi-
gration of EPCs and has been studied primarily for its
essential role in embryologic hematopoiesis, vasculogen-
esis, and cardiogenesis.12 SDF is highly conserved across
species, with human and rat forms differing in only 2 amino
acids. This chemokine interacts with the CXCR-4 receptor,
322 The Journal of Thoracic and Cardiovascular Surgery ● Auguwhich is highly expressed on EPCs, and induces transient
increases in intracellular calcium and catalyzes intracellular
actin polymerization required for cell motility.13,14 In vitro,
SDF increases the length of endothelial cell–lined tubules,
and in vivo it produces a dose-dependent increase in tissue
endothelial cell density.15 After experimental myocardial
infarction in rats, myocardial SDF expression is upregu-
lated, thus implicating the initiation of a native EPC-based
myocardial reparative mechanism.16
SDF has been administered in an ischemic rat hind-limb
model as a chemokine for transplanted EPCs, which were
expanded in vitro, resulting in increased concentrations of
these EPCs within the ischemic tissue and augmented tissue
perfusion.17 However, when SDF was administered to an
ischemic hind limb without the benefit of an expanded
circulating pool of transplanted EPCs, the extent of revas-
cularization was insufficient, and autoamputation occurred.
Therefore, we postulated that myocardial SDF therapy
alone would unlikely be effective, and instead we have
proposed an expansion of the native EPC pool through bone
marrow stimulation. In this study we devised a strategy of
endogenous myocardial repair for ischemic cardiomyopathy
through GM-CSF–mediated bone marrow stimulation and
SDF-mediated targeted EPC chemokinesis and evaluated
the effects on neovasculogenesis, ventricular remodeling,
and myocardial function.
Methods
Animal Care and Biosafety
Male Lewis rats weighing 250 to 300 g were obtained from
Charles River (Boston, Mass). Food and water were provided ad
libitum. This study was performed in accordance with the standard
humane care guidelines of the “Guide for the Care and Use of
Laboratory Animals” and the Institutional Animal Care and Use
Committee of the University of Pennsylvania, which conform to
federal guidelines.
Ischemic Cardiomyopathy Model
An established and highly reproducible rodent model of ischemic
cardiomyopathy was used.18 This model of postinfarction heart
failure also yields a peri-infarct border zone potentially amenable
to experimental therapy. Forty rats were anesthetized with ket-
amine (75 mg/kg) and xylazine (7.5 mg/kg), endotracheally intu-
bated with a 14-gauge angiocatheter, and mechanically ventilated
(Hallowell EMC, Pittsfield, Mass) with 1% isoflurane maintenance
anesthesia. A thoracotomy was performed in the left fourth inter-
costal space, and the heart was exposed. A 7-0 polypropylene
suture was placed around the mid–left anterior descending coro-
nary artery (LAD), briefly snared to visually verify the territory of
myocardial ischemia, and then ligated to produce a large antero-
lateral myocardial infarction of 30% of the left ventricle. The
extent of infarction was highly reproducible in our own studies and
has been documented in the literature as well.5,18 The thoracotomy
was closed in multiple layers over a temporary thoracostomy
catheter. Animals were implanted with identification microchips
(BioMedic Data Systems Inc, Seaford, Del) and recovered.
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PThree weeks after coronary ligation, while heart failure was
developing in the animals, the animals were randomized to 1 of 4
groups in preparation for planned reoperation (n  10 for each
group): saline control, GM-CSF only, SDF only, and SDF/GM-
CSF combined therapy. Saline control animals received 200 L of
subcutaneous saline on preoperative day 1, intraoperatively, and
on postoperative day 1 and a total of 250 L of saline through
direct intramyocardial injection with a 30-gauge needle into 5 sites
in the border zone surrounding the prior infarction. GM-CSF–
treated animals received doses of 40 g/kg liquid sargramostim
(GM-CSF) in saline (200 L total) on preoperative day 1, intra-
operatively, and on postoperative day 1 and 250 L of intramyo-
cardial saline. SDF-treated animals received 200 L of subcuta-
neous saline on preoperative day 1, intraoperatively, and on
postoperative day 1 and intramyocardial injection of 3 g/kg
SDF-1 (BD Biosciences, San Diego, Calif) in 250 L of saline into
the infarction border zone. SDF/GM-CSF–treated animals re-
ceived subcutaneous GM-CSF and intramyocardial SDF injections
as described above. The animals were then closed and recovered
for another 3 weeks.
Infarct Size Analysis
At 6 weeks after coronary ligation, after myocardial functional
analysis as described below, the hearts were explanted. The left
ventricle was filled with OCT compound (Sakura Finetek, Tor-
rance, Calif) through the aorta, and the heart was submerged in an
OCT-filled conical tube, frozen in liquid nitrogen, and stored at
80°C. By means of a cryostat, multiple slides of 10-m sections
from midway between the apex and the point of ligation were
prepared for immunohistochemical staining and infarct size anal-
ysis. Infarct size was assessed with digital planimetry software
(OpenLab, Lexington, Mass) of hematoxylin and eosin–stained
sections and compared among groups to exclude any potential
differences in myocardial infarct size among groups as possible
contributors to observed differences in hemodynamics. Further-
more, a separate group of 10 additional animals were killed 3
weeks after initial LAD ligation to confirm that there was no
modulation in infarct size during this second 3-week treatment
period, and left ventricular infarct size was determined by using
triphenyltetrazolium chloride (1%) staining (Sigma Chemicals, St
Louis, Mo).
EPC Identification
Frozen sections were washed with cold phosphate-buffered saline
(PBS) at room temperature for 10 minutes, fixed with acetone at
20°C for 5 minutes, blocked with 1% bovine serum albumin in
PBS for 30 minutes, and costained with antibodies against CD34
and VEGFR2. Sections were incubated in rabbit anti-mouse CD34
(Santa Cruz Biotech, Santa Cruz, Calif) and goat anti-mouse
VEGFR2 (R&D Systems, Minneapolis, Minn) for 1 hour at room
temperature. Sections were washed 3 times in PBS and incubated
at room temperature in the dark with 1:40 fluorescein isothiocya-
nate–conjugated swine anti-goat immunoglobulin (DakoCytoma-
tion, Carpinteria, Calif) and 1:400 rhodamine-conjugated donkey
anti-rabbit immunoglobulin (Abcam, Cambridge, Mass) secondary
antibodies. Slides were washed 3 times with PBS and mounted
with Vectashield with 4’,6-diamidino-2-phenylindole for nonspe-
cific staining of nuclei (Vector Labs, Burlingame, Calif). Quanti-
The Journal of Thoracitative analysis of colocalized antibody expression was conducted
with 40 fluorescent microscopy. Counts were conducted in a
group-blinded fashion in 4 fields per specimen along the border
zone and averaged for each heart.
Neovascularization Assessment
Frozen sections were incubated for 10 minutes at room tempera-
ture with rabbit anti-human von Willebrand factor (vWF; Dako-
Cytomation) diluted 1:300 in 1% bovine serum albumin. Slides
were then washed 3 times with PBS for 10 minutes and then
incubated in the dark at room temperature for 30 minutes with 1:40
fluorescein isothiocyanate–conjugated swine anti-rabbit immuno-
globulin (DakoCytomation). Slides were again washed and
mounted with Vectashield containing 4’,6-diamidino-2-phenylin-
dole vWF-positive blood vessels were quantified by means of 40
fluorescent microscopy in a group-blinded manner in 4 fields per
specimen along the border zone and averaged for each heart.
Ventricular Geometry Analysis
For chamber size, left ventricular cavitary diameter in both the
anteroposterior and mediolateral axes was measured on each sec-
tion and averaged. For border-zone wall thickness, on each section,
2 measurements were obtained in the immediate peri-infarct re-
gion, one on each side of the infarct, medial and lateral, just
beyond the zone of fibrosis, and averaged. Measurements were
obtained in a group-blinded manner and reported as millimeters 
SEM.
Hemodynamic Assessment
Six weeks after initial coronary ligation, when animals are typi-
cally in overt heart failure, the rats underwent median sternotomy
for myocardial contractility analysis, as previously described.19 In
brief, a 2F pressure-volume conductance catheter (Millar Instru-
ments, Inc, Houston, Tex) was inserted into the left ventricle
through the apex of the heart. Multiple cardiac functional param-
eters were measured, recorded, and analyzed with Chart v4.1.2
software (AD Instruments, Colorado Springs, Colo) and ARIA 1
Pressure Volume Analysis software (Millar Instruments). In addi-
tion to steady-state hemodynamic parameters, contractility was
determined from pressure-volume relationships obtained by reduc-
ing preload through occlusion of the inferior vena cava. Volume
measurements were calibrated by 2-point linear interpolation with
fixed-volume cuvettes of heparinized rat blood, and parallel con-
ductance was excluded with the hypertonic saline injection
technique.
Statistical Methods
Statistical analyses were performed by 1-way analysis of variance
and the Tukey-Kramer Honestly Significant Difference method to
test for differences among means. All results were expressed as
means  SEM.
Results
Infarct Size
At 3 weeks after LAD ligation, rats manifested a mean
infarct size of 29.3%  2.8% (n  10). Six weeks after
LAD ligation (3 weeks after assignment to treatment group),
c and Cardiovascular Surgery ● Volume 130, Number 2 323
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CSPinfarct sizes were statistically equivalent among all 4 groups
(saline control, 29.1%  2.3%; GM-CSF only, 31.6% 
1.8%; SDF only, 30.9%  2.9%; and SDF/GM-CSF com-
bined, 29.6%  2.4%; P  NS), thereby validating model
reproducibility, consistency among the 4 groups, and ab-
sence of infarct modulation.
EPC Identification
Quantitative analysis of immunohistochemical staining for
colocalized EPC markers revealed CD34 and VEGFR2
expression in border-zone regions of SDF/GM-CSF–treated
hearts to a far greater extent than in the other 3 groups
(Figure 1, A). This consistently colocalized expression of
CD34 and VEGFR2 likely indicates regions of immature
endothelial cell proliferation. Representative superimposed
fluorescent photomicrographs of CD34/VEGFR2 cells in
saline control and SDF/GM-CSF–treated hearts are depicted
in Figure 1, B.
Neovascularization
Microscopic analysis of immunofluorescent expression for
vWF along border-zone regions revealed a significant in-
crease in blood vessel density in SDF/GM-CSF–treated
Figure 1. A, Graph of the mean number of CD34/VEGF
the 4 groups. B, Representative immunostains of saline
VEGFR2 (red; merged  orange), and DAPI nuclei (bluanimals (44.1  5.5 vessels/high-power field [hpf]) com-
324 The Journal of Thoracic and Cardiovascular Surgery ● Augupared with animals in the saline control group (23.8  2.2
vessels/hpf, P  .007; Figure 2, A). Border-zone myocar-
dium in the GM-CSF-only and SDF-only groups exhibited
relatively small and statistically insignificant blood vessel
density increases compared with those in the saline control
group (GM-CSF only, 24.2  3.6 vessels/hpf; SDF only,
31.8  2.2 vessels/hpf). Representative vWF immunostains
of a saline control heart and an SDF/GM-CSF–treated heart
are shown in Figure 2, B.
Ventricular Geometry
Representative hematoxylin and eosin–stained sections of
SDF/GM-CSF–treated hearts and control hearts are shown
in Figure 3, A. Quantitative analysis of cavitary dilatation
and wall thinning in all hearts of all 4 groups revealed that
SDF/GM-CSF–treated animals displayed significantly less
ventricular dilation than the other 3 groups (saline control,
10.1 0.1 mm; GM-CSF only, 10.22 0.1 mm; SDF only,
9.91  0.01 mm; SDF/GM-CSF, 9.8  0.12 mm; Figure 3,
B). Marked increases in border-zone wall thickness were
also observed in SDF/GM-CSF–treated hearts (saline con-
trol, 1.41 0.16 mm; GM-CSF only, 1.43 0.11 mm; SDF
only, 1.71  0.14 mm; SDF/GM-CSF, 1.78  0.19 mm;
oexpressing cells per high-power field in hearts from
trol and SDF/GM-CSF–treated hearts for CD34 (green),R2 c
con
e).Figure 3, B).
st 2005
Woo et al Cardiopulmonary Support and Physiology
CS
PFigure 2. A, Graph of the mean number of vWF-positive blood vessels per high-powered field in each group. B,
Representative images of myocardial sections depicting vWF (green)– expressing blood vessels for SDF/GM-CSF–
treated and saline control animals. (Original magnification 40.) Arrows indicate vWF-positive vessels.Figure 3. A, Representative hematoxylin and eosin–stained cross-sections of saline control and SDF/GM-CSF–
treated hearts. Large arrows indicate where left ventricular diameter was measured, and small arrows indicate
where border-zone thickness was measured. B, Graph of the mean ventricular diameter and wall thickness for
each group.
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CSPHemodynamics
The SDF/GM-CSF–treated animals had statistically signif-
icant preservation of cardiac function compared with ani-
mals from the 3 other groups (Table 1). The SDF/GM-CSF–
treated animals had significantly improved hemodynamics
and systolic function, as measured on the basis of cardiac
output, stroke volume, maximum left ventricular pressure,
maximum dP/dt, and stroke work. SDF/GM-CSF–treated
animals also had significantly improved cardiac contractil-
ity, as indicated by an increased slope of the pressure-
volume relationship (saline control, 0.54  0.19 mm Hg/
L; GM-CSF only, 0.58  0.15 mm Hg/L; SDF only,
0.71  0.21 mm Hg/L; SDF/GM-CSF, 1.7  0.4 mm
Hg/L). Representative pressure-volume loops from each
group are shown in Figure 4.
Discussion
In an established model of ischemic cardiomyopathy, bone
marrow stimulation with GM-CSF and targeted EPC che-
mokinesis with intramyocardial SDF enhanced myocardial
neovascularization, attenuated adverse ventricular remodel-
ing, and improved ventricular function. To our knowledge,
this is the first report of this specific strategy of promoting
targeted native endothelial cell revascularization for isch-
emic cardiomyopathy.
Beyond the standard medical and surgical therapies for
ischemic cardiomyopathy, researchers have investigated
many novel strategies addressing the underlying mecha-
nisms of ventricular dysfunction. Ischemia, infarction, and
subsequent loss of myocontractile mass form a clear mech-
anism of heart failure. However, chronic myocardial isch-
emia that does not yield tissue loss can induce a spectrum of
derangements in cardiomyocyte metabolism, with marked
decoupling of energy consumption and work production
yielding an inefficient failing heart. This effect might be
particularly pronounced in the relatively ischemic and dys-
TABLE 1. Hemodynamic parameters of cardiac function 6 w
treated animals
A:
Saline/saline
(n  10)
B:
GMCSF/saline
(n  10)
Heart rate (beats/min) 185 10 184  12
Maximum pressure (mm Hg) 71.7 3.1 70.6 1.7
Maximum dP/dt (mm Hg/s) 2602 201 2756 101
Stroke volume (L) 73.7 8.3 80.6 24.6
Ejection fraction (%) 28.1 3.1 32.7 2.4
Cardiac output (mL/min) 13.3 1.3 14.5 4.6
Stroke work (mm Hg/L) 2780  781 2921 1430
Contractility slope (mm Hg/L) 0.54  0.19 0.58 0.15
Measurements were obtained by using an intraventricular pressure–volumfunctional border zone surrounding a myocardial infarct.
326 The Journal of Thoracic and Cardiovascular Surgery ● AuguFor example, in ischemic cardiomyopathy, high-energy cre-
atinine phosphate stores are diminished,20 and in patients,
decreased levels of myocardial creatine phosphate measured
by phosphorous 31 magnetic resonance spectroscopy cor-
relate highly with mortality.21 The activity of creatine ki-
nase, an enzyme that catalyzes the high-energy phosphate
transfer from creatine phosphate to adenosine diphosphate
to form adenosine triphosphate, is also decreased.22 These
factors initiate a deleterious cycle of myocardial contractile
dysfunction and ventricular dilatation. Supraphysiologic
stretch, cell-cell slippage, and geometric inefficiency with a
progressive decrease in the ratio of wall thickness to cham-
ber radius augment the tension load and promote further
detrimental remodeling.
Enhancing myocardial perfusion might reverse meta-
bolic derangements, restore energy efficiency, and reverse
heart failure. Patients with postinfarction heart failure who
have angiographic collateralization manifest improved re-
gional ventricular function.23 Cardiomyopathic patients
with anatomically amenable coronary disease also benefit
from revascularization.2 Weeks to months after successful
revascularization, patients will often exhibit increased ven-
tricular ejection fraction on transthoracic echocardiogra-
phy.24 Unfortunately, the majority of patients with heart
failure do not have coronary disease anatomically correct-
able by percutaneous or operative techniques, and
transmyocardial laser revascularization has had mixed re-
sults. Molecular and cellular revascularization strategies are
under active investigation and have included the use of
angiogenic factors that appear to act, at least in part, through
the induction of EPC-mediated neovasculogenesis. Al-
though angiogenesis is generally defined as the sprouting of
new vessels from existing vessels through the proliferation
of mature endothelial cells and vasculogenesis refers to the
embryologic formation of blood vessels from EPCs, these
s after coronary ligation among control and SDF/GM-CSF–
C:
Saline/SDF
(n  10)
D:
GM-CSF/SDF
(n  10)
Groups significantly different
from D
205 8 193  11 NS
81.1 3.5 93.9 3.2 P  .001 (A), .001 (B), .05 (C)
2886 120 3515 303 P  .01 (A), .01 (B), .05 (C)
82.5 9.0 117.8 16.8 P  .01 (A)
40.4 2.2 41.0 4.6 P  .05 (A), .05 (B)
15.7 1.2 21.3 2.7 P  .01 (A), .05 (B), .05 (C)
3727 1736 7185 973 P  .001 (A), .001 (B), .01 (C)
0.71 0.21 1.7 0.4 P  .01 (A), .01 (B), .05 (C)
nductance catheter.eekterms are often used interchangeably in the literature. EPC-
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believed to occur through a combination of angiogenic and
vasculogenic processes.25
Combining the sequentially complementary approaches
of global bone marrow stimulation and targeted EPC che-
mokinesis, we devised a strategy of endogenous myocardial
repair for ischemic cardiomyopathy. The observed lack of
efficacy of GM-CSF therapy alone possibly could be due to
the fact that multiple tissues express native SDF, and thus
bone marrow stimulation with only GM-CSF is unlikely to
yield sufficient myocardium-specific targeting of EPCs. In a
rabbit hind-limb model of ischemia, repeated daily dosing
of GM-CSF for 7 days before femoral artery ligation
yielded increased vascularity.11 This treatment approach is
limited in its extent of clinical translatability. The observed
lack of efficacy of lone intramyocardial SDF therapy is
Figure 4. Improved contractility was seen among SDF/
 21.3 L; r  0.96; n  10) when compared with cont
r  0.78; n  10; P < .01). Representative pressure-voprobably due to limitations of insufficient bone marrow
The Journal of Thoraciproduction of EPCs. In fact, the injection of only SDF into
ischemic hind limbs has been found to result in
autoamputation.17
In contrast to most research groups, which administer
therapeutic agents at the time of coronary ligation, we used
a model of ischemic cardiomyopathy in which the animals
first underwent infarction, followed by 3 weeks of remod-
eling. By waiting 3 weeks after infarction, the animals had
sufficient time to experience some degree of heart failure,
thus allowing for a more clinically relevant analysis. Also,
this model permitted the elimination of potential infarct
modulation from confounding the results. At the time of
reoperation, animals were first randomized to the different
groups to minimize any potential minor differences in ani-
mal size, infarct size, or degree of remodeling. The validity
of the proximal LAD ligation model has been confirmed by
SF–treated animals (slope, 1.7  0.4; x-intercept, 76.2
imals (slope, 0.54  0.19; x-intercept, 122.1  15.2 L;
loops for all 4 groups are displayed.GM-C
rol an
lumemultiple research groups. In our own studies of this model,
c and Cardiovascular Surgery ● Volume 130, Number 2 327
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prised 30% of the left ventricle, which is consistent with
results previously reported.18 The observation of equivalent
infarct sizes in all 4 groups in this study precludes attribut-
ing any hemodynamic differences to disparities in infarct
size. The stability in infarct size over this period of time is
also consistent with previously reported results.18 Further-
more, with regard to localization of intended therapy, in the
current study SDF was directly injected into the border
zone, where neovascularization would potentially improve
contractility, as opposed to the scar, where benefit was less
likely to be expected.
An immunofluorescent von Willebrand assay used to
label endothelial cells lining border-zone blood vessels was
useful in determining the vasculogenic states of experimen-
tal groups. As indicated by increased vessel densities in
SDF/GM-CSF–treated border zones, we have detected im-
provements in myocardial vascularity relative to hearts
treated with saline. These findings warrant further study of
regional perfusion estimations through functional vascular-
ization assessment with techniques such as radionuclide
imaging or tomato lectin histologic angiography.26 We have
previously reported in a related model that increased vas-
cularity, as evidenced by von Willebrand staining, corre-
lated with increased microsphere perfusion.5
Overall, the observed finding of a marked increase in
cells coexpressing CD34 and VEGFR2 in SDF/GM-CSF–
treated hearts compared with levels in the saline control
group warrant extensive future studies in tracking the mo-
bilization and differentiation of EPCs in this experimental
model. Bone marrow and peripheral blood flow cytometry
and further myocardial immunohistochemical analysis of
EPC markers in native, control, and SDF/GM-CSF–treated
animals immediately after treatment and at various time
points could better delineate the proliferation, mobilization,
targeting, and differentiation of the EPCs.
The effect of SDF/GM-CSF treatment on ventricular
remodeling was analyzed by using histologic sections. The
increased border-zone wall thickness and decreased cham-
ber dilatation imply an alteration in the detrimental remod-
eling process with SDF/GM-CSF therapy. These results
must be viewed within the context of the limitations of
measurement precision for submillimeter changes. Interest-
ingly, a pilot microscopic study of border-zone cardiomyo-
cyte numbers revealed more cells in the SDF/GM-CSF
group than in the saline group (40.0  5.6 vs 27.0  6.0
cells/hpf, n  5, P  .011), findings consistent with the
observed increased border-zone wall thickness and poten-
tially caused by increased regional vascularity and tissue
preservation. As an internal control, we observed no differ-
ence in the number of cardiomyocytes per high-power field
in remote myocardium between SDF/GM-CSF–treated and
saline-only hearts (63.2  3.0 vs 63.0  3.2 cells/hpf, P 
328 The Journal of Thoracic and Cardiovascular Surgery ● AuguNS). For more detailed studies into the time course progres-
sion of ventricular remodeling, serial echocardiography or
magnetic resonance imaging could be used. These imaging
modalities could potentially also provide regional contrac-
tility data.
The improved cardiac function observed in the SDF/
GM-CSF group is significant when compared with that seen
in the other 3 groups. When comparing these animals with
native noninfarcted animals, the cardiac function appears to
be close to normal. For example, in a separate group of age-
and weight-matched native Lewis rats (n  5) studied for
hemodynamics, heart rate was 194  15 beats/min, maxi-
mum pressure was 103 12.4 mm Hg, maximum dP/dt was
4582 346 mm Hg/s, ejection fraction was 39.4% 4.9%,
cardiac output was 25.7  5.5 mL/min, and contractility
slope was 1.8  0.3 mm Hg/L.
Although not directly investigated in this study, the im-
proved hemodynamics might be the result of a combined
effect of somewhat improved ventricular geometry and in-
creased border-zone contractility from restored vasculariza-
tion. The ability to demonstrate reversal of regional border-
zone cardiomyocyte ischemia in future studies would
strongly support this hypothesis. A possible alternative ex-
planation for many of the observed findings would be the
stimulation of cardiac progenitor cells. This seems less
likely with data illustrating increases in endothelial cell–
specific markers. There also appears to be an increasing
body of evidence to suggest that bone marrow–derived
progenitor cells differentiate primarily into endothelial cells
and only rarely into cardiomyocytes.27,28 In a unique clin-
ical model of myocardial repair, female donor hearts (XX)
transplanted into male recipients (XY), when examined
later for Y-chromosome positive cells, have demonstrated
predominantly endothelial lineage cells and very few
cardiomyocytes.29
The EPC proliferation and targeting strategy described in
this report could potentially be applied to a variety of
ischemic disease processes. One could also envision SDF-
coated intravascular grafts, stents, prosthetic valves and
rings, patches, anastomotic devices, and ventricular assist
devices to promote endothelialization.
In summary, this study describes GM-CSF mobilization
and intramyocardial SDF chemokinesis of EPCs to form a
unique neovascularization treatment strategy for ischemic
cardiomyopathy and demonstrates enhanced vascularity, at-
tenuated adverse ventricular remodeling, and improved
myocardial function.
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